Following some safety setbacks and years of generic competition, Takeda is calling it quits on the gout drug Uloric in the U.S. More: Takeda bids adieu to Uloric after gout med's gradual fade from glory Source: fierce
read moreBased on a survey of doctors treating patients for pulmonary arterial hypertension, analysts at Leerink Partners believe that Merck’s Winrevair could overcome a slow ramp in 2024 and “have strong uptake growth” in 2025. More: After slow rollout, Merck's Winrevair
read moreWhile Fujifilm Diosynth Biotechnologies isn’t immune to the challenges facing the broader CDMO industry, the company’s long-running expansion journey—and its ability to snare high-profile pharma clients—has blunted many of the pressures met by its peers. More: Fujifilm Diosynth CEO heralds
read moreAs users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines Agency has embarked on its own metamorphosis from one text-based social media service to the other. More: Seeking new
read moreMerck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. More: Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal in GI
read moreDepartment of Health and Human Services secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing Merck over the marketing and sale of one of its vaccines. RFK Jr.’s plans
read more© 1994 - 2026 B.M. Pharmaceuticals